171 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
9 May 24
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results
4:12pm
, or impairing employee productivity; unexpected adverse side effects or inadequate efficacy of the Company’s product candidates that may limit
8-K
CRNX
Crinetics Pharmaceuticals Inc
4 Apr 24
Departure of Directors or Certain Officers
4:52pm
of the Company, as well as non-employee directors of the Company.
Pursuant to the Plan, participants will be able to elect to defer all or a portion of certain
S-3ASR
kyfd10n 73quhf60
19 Mar 24
Automatic shelf registration
4:05pm
8-K
EX-99.2
35q10ybcqx7
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
EX-99.2
y9fczq
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
S-8 POS
wfftfd qgt
1 Mar 24
Registration of securities for employees (post-effective amendment)
4:41pm
8-K
EX-10.1
tuh4lck
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
S-8
8ueqv68xdlgry
28 Feb 24
Registration of securities for employees
6:04pm
S-8
EX-5.1
3sms yiu9ryvfbg5jf
28 Feb 24
Registration of securities for employees
6:04pm
S-8
bibdxchz2
28 Feb 24
Registration of securities for employees
6:04pm
8-K
EX-99.1
1q992k0
28 Feb 24
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
7glno7 ggspdq9vp0m
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.2
kh4ez23roekla 1w
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-3.1
l3v9 yiiqi3
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
S-8
ra2wnc1g5xg4au
7 Nov 23
Registration of securities for employees
4:31pm